Who makes ABI-110 Medium Dose?

ABI-110 Medium Dose is developed by Avirmax Biopharma Inc.

What development phase is ABI-110 Medium Dose in?

ABI-110 Medium Dose is in Phase 1.

Last reviewed 2026-04-23 · How we verify

ABI-110 Medium Dose

Avirmax Biopharma Inc · Phase 1 active Small molecule

At a glance

Generic name	ABI-110 Medium Dose
Sponsor	Avirmax Biopharma Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABI-110 Medium Dose CI brief — competitive landscape report
ABI-110 Medium Dose updates RSS · CI watch RSS
Avirmax Biopharma Inc portfolio CI